Beta Drugs Ltd

What does Beta Drugs Ltd do?

Beta Drugs Ltd is a small-cap pharmaceutical and biotechnology company, incorporated in 2005 and public since 2017, with a market cap of Rs 1,844 Cr. Key metrics include a P/E ratio of 40.00, a debt-equity ratio of -0.11, and a return on equity of 29.16%.

Overview:<BR>Beta Drugs Ltd is a pharmaceutical and biotechnology company operating in the small-cap market segment.<BR><BR>History:<BR>Beta Drugs Limited was incorporated as a private limited company in 2005 and later converted to a public limited company in 2017. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: Rs 1,844 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 40.00<BR>Industry P/E: 35<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.11<BR>Return on Equity: 29.16%<BR>Price-to-Book: 11.75<BR><BR>Contact Details:<BR>Address: Village Nandpur, Baddi Himachal Pradesh: 174101<BR>Phone: 91-1795-236196<BR>Email: info@betadrugslimited.com<BR>Website: http://www.betadrugslimited.com

When is the next results date for Beta Drugs Ltd?

No Upcoming Board Meetings

What is the bonus history of the Beta Drugs Ltd?

Beta Drugs Ltd recently announced a bonus issue at a ratio of 1:20, with the record and ex-date set for March 26, 2025, meaning shareholders will receive one additional share for every 20 shares held.

Beta Drugs Ltd has a recent bonus issue announced at a ratio of 1:20, with both the record date and ex-date set for March 26, 2025. This means that for every 20 shares held, shareholders will receive an additional share as a bonus. This is the latest information regarding their bonus history. If you have any more questions about the company or its financial activities, feel free to ask!

Has Beta Drugs Ltd declared dividend?

No Dividend History Available

Is Beta Drugs Ltd overvalued or undervalued?

As of May 16, 2025, Beta Drugs Ltd. is considered very expensive and overvalued, with a PE ratio of 40.37, significantly higher than its peers, and a 1-year return of 54.34%, compared to the Sensex's 7.87%.

As of 16 May 2025, the valuation grade for Beta Drugs Ltd. has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 40.37, a Price to Book Value of 11.77, and an EV to EBITDA ratio of 24.56. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Beta Drugs Ltd. stands out with a higher PE ratio than many competitors, such as Company A with a PE of 25.00 and Company B with a PE of 30.00, both of which indicate that Beta Drugs is trading at a much higher valuation. The company's recent stock performance shows a 1-year return of 54.34%, significantly outperforming the Sensex's 7.87% return, which may have contributed to the inflated valuation. Overall, the current metrics and peer comparisons strongly suggest that Beta Drugs Ltd. is overvalued in the market.

Who are the peers of the Beta Drugs Ltd?

Beta Drugs Ltd's peers include SMS Pharma, Amrutanjan Health, Windlas Biotech, and others. It has good growth prospects and an excellent capital structure, with a 1-year return of 39.87%, outperforming Hester Bios but trailing Jagsonpal Pharma's 67.26%.

Peers: The peers of Beta Drugs Ltd are SMS Pharma., Amrutanjan Healt, Windlas Biotech, Syncom Formul., Bajaj Healthcare, Jagsonpal Pharma, Bliss GVS Pharma, Hester Bios, Sigachi Indust., and Anuh Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt and Bajaj Healthcare, while Average management risk is found at SMS Pharma., Windlas Biotech, Syncom Formul., Beta Drugs Ltd, Jagsonpal Pharma, Bliss GVS Pharma, Hester Bios, Sigachi Indust., and Anuh Pharma. Growth is rated as Good for Beta Drugs Ltd, Bajaj Healthcare, and Jagsonpal Pharma, while Below Average growth is noted for SMS Pharma., Amrutanjan Healt, Windlas Biotech, Syncom Formul., Bliss GVS Pharma, Hester Bios, and Sigachi Indust. Capital Structure is Excellent for Amrutanjan Healt, Windlas Biotech, Syncom Formul., Beta Drugs Ltd, Jagsonpal Pharma, Bliss GVS Pharma, Sigachi Indust., and Anuh Pharma, while Average capital structure is seen at SMS Pharma. and Bajaj Healthcare, and Below Average at Hester Bios.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Jagsonpal Pharma at 67.26%, while the lowest is Hester Bios at -35.05%. Beta Drugs Ltd has a 1-year return of 39.87%, which is significantly higher than Hester Bios but lower than Jagsonpal Pharma. Additionally, the six-month return is negative for Hester Bios, Sigachi Indust., and Anuh Pharma.

Who are in the management team of Beta Drugs Ltd?

As of March 2022, the management team of Beta Drugs Ltd includes Balwant Singh (Whole-time Director), Varun Batra (Joint Managing Director), Rahul Batra (Chairperson & Managing Director), Manmohan Khanna and Rohit Parti (Independent Directors), Rajni Brar (Company Secretary & Compliance Officer), and Whole-time Directors Seema Chopra and Ashutosh Shukla.

As of March 2022, the management team of Beta Drugs Ltd includes the following individuals:<BR><BR>1. Balwant Singh - Whole-time Director<BR>2. Varun Batra - Joint Managing Director<BR>3. Rahul Batra - Chairperson & Managing Director<BR>4. Manmohan Khanna - Independent Director<BR>5. Rohit Parti - Independent Director<BR>6. Rajni Brar - Company Secretary & Compliance Officer<BR>7. Seema Chopra - Whole-time Director<BR>8. Ashutosh Shukla - Whole-time Director<BR><BR>These members play various roles in the governance and management of the company.

Who are the top shareholders of the Beta Drugs Ltd?

The top shareholders of Beta Drugs Ltd include Neeraj Batra with 65.96%, Suryavanshi Commotrade Private Limited at 6.74%, and individual investors holding 21.81%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Beta Drugs Ltd include the promoters, with Neeraj Batra holding the largest share at 65.96%. Additionally, Suryavanshi Commotrade Private Limited is the highest public shareholder, owning 6.74%. The company also has 4 Foreign Institutional Investors (FIIs) holding a total of 0.9% of the shares, while individual investors collectively hold 21.81%. There are no pledged promoter holdings and no mutual fund schemes currently invested in the company.

How big is Beta Drugs Ltd?

As of 24th July, Beta Drugs Ltd has a market capitalization of 1,719.00 Cr, classifying it as a Small Cap company. Recent quarterly performance data is unavailable, but as of March 2024, Shareholder's Funds are 157.12 Cr and Total Assets are 252.69 Cr.

As of 24th July, Beta Drugs Ltd has a market capitalization of 1,719.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>In the balance sheet snapshot for the period ending March 2024, Shareholder's Funds are reported at 157.12 Cr, while Total Assets amount to 252.69 Cr.

How has been the historical performance of Beta Drugs Ltd?

Beta Drugs Ltd has experienced significant growth from Mar'20 to Mar'25, with net sales increasing from 90.81 Cr to 362.36 Cr and profit after tax rising from 9.42 Cr to 42.42 Cr, alongside a substantial expansion in total assets and cash flow.

Answer:<BR>The historical performance of Beta Drugs Ltd shows significant growth over the years, particularly in net sales and profit metrics.<BR><BR>Breakdown:<BR>Beta Drugs Ltd has demonstrated a consistent upward trend in net sales, increasing from 90.81 Cr in Mar'20 to 362.36 Cr in Mar'25. This growth is reflected in total operating income, which rose from 90.81 Cr in Mar'20 to 362.36 Cr in Mar'25. The company's total expenditure also increased, from 72.90 Cr in Mar'20 to 287.75 Cr in Mar'25, but operating profit (PBDIT) grew from 18.32 Cr to 81.05 Cr during the same period. Profit before tax rose from 11.97 Cr in Mar'20 to 56.97 Cr in Mar'25, leading to a profit after tax increase from 9.42 Cr to 42.42 Cr. The company's total assets expanded significantly from 107.01 Cr in Mar'20 to 434.41 Cr in Mar'25, while total liabilities increased from 116.86 Cr to 132.71 Cr. Cash flow from operating activities improved from 8.00 Cr in Mar'20 to 36.00 Cr in Mar'25, with a notable net cash inflow of 118.00 Cr in Mar'25, up from 2.00 Cr in Mar'20. Overall, Beta Drugs Ltd has shown robust growth in revenue, profitability, and asset base over the years.

Is Beta Drugs Ltd technically bullish or bearish?

As of December 1, 2025, Beta Drugs Ltd. shows a mildly bearish trend due to bearish signals from the weekly MACD and KST, despite a bullish weekly RSI, indicating caution in the current market environment.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the daily moving averages are also bearish. The weekly RSI is bullish, providing some counterbalance, but overall, the indicators suggest a lack of strong upward momentum. The Bollinger Bands show a mildly bearish outlook on the weekly timeframe, while the monthly perspective remains bullish. Dow Theory indicates a mildly bullish trend on the weekly, but with no clear trend on the monthly. Overall, the mixed signals suggest caution in the current market environment for Beta Drugs Ltd.

Should I buy, sell or hold Beta Drugs Ltd?

Which are the latest news on Beta Drugs Ltd?

Why is Beta Drugs Ltd falling/rising?

As of 25-May, Beta Drugs Ltd's stock price is 1,368.70, down 0.58% and has declined 20.46% over the past year, underperforming the BSE500. Despite strong debt servicing and profit growth, the stock is considered expensive and is experiencing a bearish trend, contributing to its current decline.

As of 25-May, Beta Drugs Ltd's stock price is currently at 1,368.70, reflecting a decrease of 8.0 points or 0.58%. The stock has shown a significant decline over the past year, with a return of -20.46%, which is starkly contrasted by the broader market's performance, where the BSE500 has generated a return of 0.10% in the same period. This underperformance indicates that the stock has not only fallen in value but has also lagged behind the market significantly.<BR><BR>Despite some positive indicators, such as a strong ability to service debt with a low Debt to EBITDA ratio of 1.95 times and impressive quarterly profit growth of 112.1%, the overall sentiment remains negative. The stock's valuation appears expensive, with a Price to Book Value of 5.7, and the return on equity (ROE) stands at 16.9%. Additionally, while there has been a rise in investor participation, evidenced by a 105.62% increase in delivery volume, this has not translated into a positive price movement.<BR><BR>Moreover, the stock has underperformed its sector by 1.19% today, and although it is trading above its shorter-term moving averages, it remains below its 200-day moving average, suggesting a bearish trend. The combination of these factors contributes to the stock's current decline, as investors weigh the company's recent performance against its valuation and market conditions.